Virtu Financial LLC Makes New $390,000 Investment in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Virtu Financial LLC purchased a new position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) during the 3rd quarter, Holdings Channel.com reports. The institutional investor purchased 13,526 shares of the company’s stock, valued at approximately $390,000.

Several other hedge funds and other institutional investors have also made changes to their positions in APLS. HighVista Strategies LLC raised its holdings in shares of Apellis Pharmaceuticals by 4.1% in the 2nd quarter. HighVista Strategies LLC now owns 7,566 shares of the company’s stock valued at $290,000 after purchasing an additional 300 shares in the last quarter. Amalgamated Bank raised its stake in Apellis Pharmaceuticals by 5.4% in the second quarter. Amalgamated Bank now owns 6,995 shares of the company’s stock valued at $268,000 after buying an additional 359 shares in the last quarter. KBC Group NV lifted its holdings in Apellis Pharmaceuticals by 34.8% during the 3rd quarter. KBC Group NV now owns 2,632 shares of the company’s stock worth $76,000 after buying an additional 679 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Apellis Pharmaceuticals by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company’s stock worth $130,000 after acquiring an additional 781 shares in the last quarter. Finally, Wolverine Asset Management LLC acquired a new position in shares of Apellis Pharmaceuticals during the 3rd quarter worth about $27,000. Hedge funds and other institutional investors own 96.29% of the company’s stock.

Apellis Pharmaceuticals Stock Performance

NASDAQ:APLS opened at $33.66 on Tuesday. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73. The firm has a market cap of $4.19 billion, a price-to-earnings ratio of -16.58 and a beta of 0.94. The firm’s fifty day moving average price is $29.78 and its 200 day moving average price is $34.67. Apellis Pharmaceuticals, Inc. has a 1-year low of $24.34 and a 1-year high of $73.80.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.14). The firm had revenue of $196.83 million during the quarter, compared to analysts’ expectations of $200.00 million. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The firm’s revenue was up 78.3% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.17) EPS. On average, sell-side analysts expect that Apellis Pharmaceuticals, Inc. will post -1.72 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on APLS. Bank of America decreased their target price on Apellis Pharmaceuticals from $61.00 to $47.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. JPMorgan Chase & Co. reduced their price objective on shares of Apellis Pharmaceuticals from $64.00 to $57.00 and set an “overweight” rating for the company in a research report on Friday, September 13th. Oppenheimer dropped their target price on shares of Apellis Pharmaceuticals from $65.00 to $40.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 6th. Piper Sandler reduced their price target on shares of Apellis Pharmaceuticals from $40.00 to $32.00 and set a “neutral” rating for the company in a research report on Wednesday, November 6th. Finally, Scotiabank dropped their price objective on Apellis Pharmaceuticals from $35.00 to $30.00 and set a “sector perform” rating on the stock in a report on Wednesday, November 6th. Seven analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $49.94.

Apellis Pharmaceuticals Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).